Asymchem Laboratories (Tianjin) Co., Ltd.
SZSE:002821.SZ
149 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 7,750.738 | 10,255.325 | 4,638.834 | 3,149.69 | 2,459.986 | 1,834.878 | 1,423.033 | 1,103.195 | 830.608 | 716.207 | 542.758 | 424.399 | 405.691 |
| Cost of Revenue
| 3,949.24 | 5,397.598 | 2,582.396 | 1,683.5 | 1,340.584 | 981.674 | 686.731 | 533.916 | 430.085 | 404.448 | 299.532 | 228.24 | 217.203 |
| Gross Profit
| 3,801.498 | 4,857.727 | 2,056.438 | 1,466.19 | 1,119.401 | 853.204 | 736.302 | 569.279 | 400.522 | 311.759 | 243.226 | 196.159 | 188.488 |
| Gross Profit Ratio
| 0.49 | 0.474 | 0.443 | 0.466 | 0.455 | 0.465 | 0.517 | 0.516 | 0.482 | 0.435 | 0.448 | 0.462 | 0.465 |
| Reseach & Development Expenses
| 683.96 | 708.891 | 387.478 | 258.934 | 192.522 | 155.178 | 97.237 | 70.48 | 65.095 | 52.743 | 44.243 | 40.13 | 0 |
| General & Administrative Expenses
| 271.256 | 235.443 | 153.293 | 80.047 | 77.105 | 63.819 | 55.819 | 34.213 | 24.224 | 22.035 | 16.406 | 95.435 | 76.189 |
| Selling & Marketing Expenses
| 196.424 | 150.19 | 99.559 | 84.253 | 87.529 | 74.369 | 53.533 | 43.049 | 36.587 | 31.007 | 26.4 | 24.908 | 25.576 |
| SG&A
| 888.603 | 385.632 | 252.852 | 164.3 | 164.634 | 138.189 | 109.352 | 77.262 | 60.811 | 53.043 | 42.806 | 120.342 | 101.765 |
| Other Expenses
| -20.718 | 591.091 | 240.416 | 151.952 | 119.831 | -0.765 | 2.491 | 10.621 | -0.906 | 11.391 | 13.926 | 14.657 | 12.396 |
| Operating Expenses
| 1,593.281 | 1,685.614 | 880.746 | 575.186 | 476.987 | 401.108 | 252.535 | 271.73 | 220.654 | 182.014 | 144.979 | 122.248 | 104.166 |
| Operating Income
| 2,208.217 | 3,730.78 | 1,192.362 | 816.894 | 623.668 | 461.387 | 419.589 | 314.923 | 200.46 | 121.242 | 86.955 | 69.167 | 77.176 |
| Operating Income Ratio
| 0.285 | 0.364 | 0.257 | 0.259 | 0.254 | 0.251 | 0.295 | 0.285 | 0.241 | 0.169 | 0.16 | 0.163 | 0.19 |
| Total Other Income Expenses Net
| 351.082 | -5.836 | 0.587 | -2.538 | -0.081 | 8.526 | -61.687 | 27.92 | 19.686 | 2.756 | 2.549 | 9.902 | 5.236 |
| Income Before Tax
| 2,559.299 | 3,724.944 | 1,192.949 | 814.356 | 623.587 | 460.622 | 422.08 | 325.469 | 199.554 | 132.502 | 100.796 | 83.813 | 89.559 |
| Income Before Tax Ratio
| 0.33 | 0.363 | 0.257 | 0.259 | 0.253 | 0.251 | 0.297 | 0.295 | 0.24 | 0.185 | 0.186 | 0.197 | 0.221 |
| Income Tax Expense
| 306.31 | 430.314 | 123.694 | 92.304 | 69.723 | 54.171 | 62.032 | 49.865 | 29.837 | 18.796 | 16.029 | 12.42 | 13.772 |
| Net Income
| 2,268.81 | 3,301.635 | 1,069.274 | 722.091 | 553.864 | 428.295 | 341.288 | 252.735 | 153.545 | 101.792 | 74.729 | 60.251 | 65.373 |
| Net Income Ratio
| 0.293 | 0.322 | 0.231 | 0.229 | 0.225 | 0.233 | 0.24 | 0.229 | 0.185 | 0.142 | 0.138 | 0.142 | 0.161 |
| EPS
| 6.26 | 9.02 | 3.15 | 2.21 | 1.73 | 1.34 | 1.08 | 0.99 | 0.61 | 0.4 | 0.3 | 0.24 | 0.26 |
| EPS Diluted
| 6.26 | 9 | 3.13 | 2.2 | 1.71 | 1.33 | 1.06 | 0.99 | 0.61 | 0.4 | 0.3 | 0.24 | 0.26 |
| EBITDA
| 2,695.077 | 4,032.898 | 1,435.779 | 994.111 | 768.533 | 559.618 | 510.799 | 398.164 | 254.249 | 189.326 | 146.533 | 106.037 | 107.534 |
| EBITDA Ratio
| 0.348 | 0.393 | 0.31 | 0.316 | 0.312 | 0.305 | 0.359 | 0.361 | 0.306 | 0.264 | 0.27 | 0.25 | 0.265 |